Accendra Health Reports Lower Revenue but Narrower Losses on Both Windows in Continuing-Operations Filing

Bottom line

3 per diluted share; the operating line showed a loss of -$35,150,000 versus a loss of -$39,710,000; and net income attributable to the parent was a loss of -$89,070,000 against a loss of -$869,058,000. 6 per diluted share; operating income (loss) is -$18,025,000 compared with -$19,919,000; and net income (loss) attributable to the parent is -$95,537,000 against -$894,040,000. - On every line and on both reported windows, the bottom line remains a loss versus a loss in the prior year, and revenue is lower year over year; the only directional changes the filing evidence authorizes are an authorized-direction increase on each loss line (smaller loss) and an authorized-direction decrease on revenue, with no single driver named.

- The filing evidence does not attribute this change to any single cause. - The source narrative is the company's unaudited condensed consolidated financial statements for period-ended-2026-06-30 (continuing-operations basis following the P&HS divestiture), drawn from the basis-of-presentation and consolidation policy summarized under Note 1, with discontinued-operations detail referenced through Note 2 and accounting policy numbering consistent with Note 1; the Part II items present in this filing include Item 1 (Legal Proceedings, Risk Factors, Unregistered Sales of Equity), Item 1A (Risk Factors and Unregistered Sales of Equity Securities and Use of Proceeds), Item 2 (Unregistered Sales of Equity Securities and Use of Proceeds, Other Information), Item 3 (Quantitative and Qualitative Disclosures About Market Risk, Controls and Procedures), Item 4 (Controls and Procedures, Legal), Item 5 (Other Information, Exhibits, Signatures), and Item 6 (Exhibits, Signatures), while fair-value hierarchy tiers Level 1, Level 2, and Level 3 and policy notes Note 5 and Note 6 frame the recurring measurement disclosures.

- Scope and limits of this section: the analysis covers only the income-statement dimensions listed above for the three- and six-month windows; cash-flow figures and per-share input counts for the EPS line are not part of this section's fact catalog and are left to later sections, and the The filing evidence contains no peer or industry comparison. means no peer or industry comparison is supplied here. - Readers modeling similar windows can place these reported figures alongside the structured returns covered by the ROI Calculator when comparing loss-narrowing trends across periods.

Financial performance

- YOY - The six-month reporting window for ACCENDRA HEALTH INC/VA/ (ACH, filing 10-Q for period-ended-2026-06-30, accession 0001104659-26-093177) shows a top-line decline on a year-over-year basis: Revenue from Contract with Customer, Excluding Assessed Tax moved from $1,355,801,000 USD in the prior-year comparative to $1,241,014,000 USD in the current year-to-date period, and the three-month line moved in the same direction, from $681,917,000 USD to $613,234,000 USD. The filing evidence does not attribute this change to any single cause.

- Operating Income (Loss) was an operating loss on both comparative frames; the authorized direction is an increase (a smaller loss) on a year-over-year basis, moving from -$19,919,000 USD to -$18,025,000 USD for the six-month view and from -$39,710,000 USD to -$35,150,000 USD for the three-month view. The authorized transition is loss to loss on both. The filing evidence does not attribute this change to any single cause.

- Net Income (Loss) Attributable to Parent stayed negative across the comparable windows; the authorized direction is an increase (a smaller loss) year over year, moving from -$894,040,000 USD to -$95,537,000 USD for the year-to-date period and from -$869,058,000 USD to -$89,070,000 USD for the quarter. The authorized transition is loss to loss on both. The filing evidence does not attribute this change to any single cause.

16 per diluted share USD/SHARES for the quarter; the authorized transition is loss to loss on both frames. The filing evidence does not attribute this change to any single cause. - QOQ - Within the year-to-date window, the three-month operating and bottom-line lines provide the sequential comparison baseline against the six-month cumulative results; the operating line and the parent line show a smaller three-month loss compared with the first-half aggregate loss, while revenue embeds a quarter-over-quarter pattern inside the half-year total.

The filing evidence does not attribute this change to any single cause. - GUIDANCE - The filing evidence does not contain a management forward-looking guidance statement, an outlook range, or a quantified projection for revenue, operating income, or earnings per share. The cited narrative in Note 1 and Note 2 discusses accounting estimates, revenue recognition policy, and the Receivables Sale Program rather than forward guidance, and management does not provide a direction or magnitude for the upcoming quarter.

The filing evidence does not attribute this change to any single cause. - EXPECTATIONS - The only expectation setting disclosed in the filing relates to revenue under stand-ready arrangements with third-party payors, where management states revenue is recognized over the month that members are entitled to healthcare services using the monthly contractual rate for each covered member, as discussed in Note 1. This is a recognition policy, not a forecast of demand or pricing.

The filing evidence contains no peer or industry comparison and does not break out segment-level detail for the reported dimensions. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

The filing evidence does not attribute this change to any single cause. - Counter-evidence and unknowns - The Receivables Sale Program and the subsequent Amended Receivables Sale Program, described within Note 1 and the cited narrative, indicate that liquidity and balance-sheet management activities continued during the period, including sales of accounts receivable with specific proceeds and loss-on-sale amounts disclosed within selling, general, and administrative expenses. The filing does not connect these activities directly to the year-over-year movement in revenue, operating loss, or net loss; any link between the receivables program and the reported performance gaps is not stated in the evidence.

The filing evidence does not attribute this change to any single cause. - Readers who want a reference frame for profit-and-loss reporting conventions can review the Covista Inc. Reports Higher Revenue, Operating Income, Net Income, and Diluted EPS Across the Twelve-Month Period Versus the Prior-Year Comparative, With Each Line Remaining Profitable Year Over Year insight, which compares to the present filing only at the level of reporting structure, not financial outcome.

Operating drivers and segments

Accendra Health, Inc. reports a single operating and reporting segment across its continuing operations, so segment-level margin commentary is not applicable for 10-Q filed under accession 0001104659-26-093177 for period-ended-2026-06-30. The consolidated revenue line, Revenue from Contract with Customer, Excluding Assessed Tax, is presented in two windows: the three-month reporting period at $613,234,000 USD and the six-month year-to-date period at $1,241,014,000 USD, each compared with the prior-year comparatives of $681,917,000 USD and $1,355,801,000 USD respectively. The authorized year-over-year direction for revenue is a decrease in both windows, with no authorized cause. The operating result is a loss on every line presented: Operating Income (Loss) for the three-month period is -$35,150,000 USD against a prior-period loss of -$39,710,000 USD, and for the six-month period the figure is -$18,025,000 USD against a prior-period loss of -$19,919,000 USD. The authorized direction for operating result is an increase (a smaller loss) in both windows, with the authorized transition from loss to loss. Because the company reports a single segment, there is no segment-mix or segment-margin story to separate; readers weighing the change must look to the consolidated figures alone. The filing evidence contains no peer or industry comparison.

Management frames the period through three structural items discussed in the cited notes and Note 1. First, certain prior period amounts have been reclassified to conform to current year presentation, which the reader should keep in mind when comparing the two windows. Second, on a date in October the company entered into an Equity Purchase Agreement to sell the P&HS business for an aggregate cash consideration subject to working-capital and other adjustments, and in accordance with GAAP that business is presented as discontinued operations and excluded from continuing operations for all periods presented; per the cited note, with the exception of Note 2, the Notes reflect continuing operations only. Third, the company entered into a Receivables Sale Program and later an Amended and Restated Receivables Sale Program under which accounts receivable were sold on a limited-recourse basis and removed from the balance sheet, with cash proceeds and losses on sale (including professional fees) recorded in selling, general, and administrative expenses; the cited note also flags that estimates involving variable consideration, reimbursement uncertainty, and delays between service date and billing are inherent in recording net revenue and accounts receivable at net realizable value.

Independent reading. The continuing-operations revenue line is lower than the prior-year comparative on both reported windows, and the operating result remains a loss in both the current and prior periods, narrowing in the authorized direction but still negative. The filing evidence does not attribute this change to any single cause. No peer or industry benchmark is available in the filing evidence, so margin pressure cannot be triangulated externally. Readers building a cross-issuer view can place this filing alongside filings such as the Covista Inc. Reports Higher Revenue, Operating Income, Net Income, and Diluted EPS Across the Twelve-Month Period Versus the Prior-Year Comparative, With Each Line Remaining Profitable Year Over Year insight to contrast a profitable revenue-and-profit improvement against Accendra's revenue contraction paired with a still-loss operating result.

Cash flow and capital

- Reported facts (cash flow) - For the six-month year-to-date period, Net Cash Provided by (Used in) Financing Activities was $124,477,000 in the prior-year comparative and -$220,894,000 in the current period, marking an authorized decrease, with the prior period positive and the current period negative. - For the same six-month window, Net Cash Provided by (Used in) Investing Activities was -$101,117,000 in the prior year and $22,680,000 in the current year, marking an authorized increase, with the prior period negative and the current period positive.

- Payments to Acquire Property, Plant, and Equipment were $103,416,000 in the prior six-month period and $89,232,000 in the current six-month period, marking an authorized decrease, with both periods reporting a positive capital expenditure outflow. - Reported facts (balance sheet) - As of the balance sheet date, Cash and Cash Equivalents, at Carrying Value stood at $7,651,000. - As of the same balance sheet date, Accounts Payable, Current was $352,798,000.

- Management explanations and disclosed context - Management describes the company as a healthcare services provider that recognizes product revenue on transfer of control and rental revenue on a straight-line basis over the typical non-cancellable rental period, with capitation arrangements recognized over the month members are entitled to services. - Management discloses a principal recapture item classified within other liabilities, tied to the Balance Sheet Optimization Transaction and to the Secured Notes, both defined and described in Note 5; the cited note states that the principal recapture liability does not represent a cash-settled obligation and is amortized through interest expense, net over the life of the Secured Notes.

- Management notes that the assumptions used to value financial instruments follow the three-tier hierarchy in Level 1, Level 2, and Level 3, and that the carrying amounts of cash, receivables, payables, and accrued payroll approximate fair value because of the short-term nature of those instruments. - Management describes the Amended Receivables Sale Program under which the company performs servicing and collection actions for the Purchasers while retaining no beneficial interest in the receivables sold; the program has a scheduled termination date in October of the relevant year, and the company states that no acquisition-related charges were incurred in the current three- and six-month windows after the mutual termination of the Rotech Merger Agreement.

- Analyst inference - Read together, the current six-month investing line shifted to a positive figure while financing swung negative and capital spending contracted, suggesting a change in the composition of the company’s funding sources during the period. - Because the filing describes the principal recapture as a non-cash item amortized into interest expense rather than a near-term cash outflow, the negative financing reading does not by itself imply a strained liquidity position; the cash balance at the balance sheet date is the cleaner reference point for any near-term liquidity framing.

- The short-term nature of cash, receivables, payables, and accrued payroll under Level 3 means the balance sheet items disclosed here likely track their carrying values closely. - Counter-evidence and limitations - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for this dimension. - Unknowns - The filing does not disclose an operating cash flow figure in this section’s catalog, so the operating leg of the cash flow statement is not addressed here. - The catalog does not list long-term debt balances, lease obligations, or shareholder equity totals, so leverage and net-cash positions are not characterized in this section.

- The filing does not disclose any dividend, repurchase, or other return-of-capital action in the cited evidence, so capital allocation beyond investing and financing cash movements is left unaddressed.

Peer and historical context

- The historical lens for this filing is limited to year-over-year self-comparison across the three-month and six-month reporting windows; the filing evidence carries no external peer or industry benchmark. - Both reporting windows show a less negative net loss attributable to parent and a less negative operating loss versus the prior-year comparatives, paired with a lower revenue print on each window. - The pattern is therefore one of top-line softness alongside an operating-result that, while still in loss territory, narrowed relative to the prior-year periods. - Where a transition between periods is described, it remains within the loss-to-loss band for net income and operating income, and within the positive band for revenue.

- The prior-year comparatives for the same half-year and quarter are themselves negative on the net income and operating lines, so the apparent improvement in the current windows is measured against an already loss-making base. - The revenue decline on both reported windows runs in the opposite direction to the operating-line improvement, which means a margin or mix effect, rather than a top-line effect, would have to explain the narrower operating loss; the cited evidence does not separate those drivers. - The filing evidence does not attribute this change to any single cause.

Scenario analysis

The reported figures for ACCENDRA HEALTH INC/VA/ on 10-Q for period-ended-2026-06-30 under accession 0001104659-26-093177 provide the floor for three conditional paths. Both the three-month reporting period and the six-month year-to-date period show a year-over-year decrease in Revenue from Contract with Customer, Excluding Assessed Tax, paired with a year-over-year increase in Net Income (Loss) Attributable to Parent that still leaves the bottom line as a loss on both reported windows. Against that mixed backdrop, a base case assumes the revenue trend that pulled the top line lower continues, while losses remain but narrow relative to the prior-year comparative.

The upside scenario assumes the favorable bottom-line direction already visible in the reported data extends further on both the three-month and six-month year-to-date windows, with Net Income (Loss) Attributable to Parent continuing to move in the direction of profitability while remaining a loss. Revenue from Contract with Customer, Excluding Assessed Tax on the three-month and six-month year-to-date windows is also assumed to stop declining and stabilize in this path. The filing evidence does not attribute this change to any single cause. Whether any operational initiative can lift either line is not addressed in the cited evidence, so the path simply extends the directional move already shown rather than attributing it to a driver.

The downside scenario assumes Revenue from Contract with Customer, Excluding Assessed Tax contracts further versus the prior-year comparative on the three-month and six-month year-to-date periods, and Net Income (Loss) Attributable to Parent widens from a smaller loss to a larger loss on both windows, undoing the directional move already visible in the reported data. The filing evidence does not attribute this change to any single cause. A downside driver cannot be named from the cited notes. The recurring nature of certain non-cash items, including intangible amortization tied to past acquisition activity and the ratable interest-expense treatment of the principal recapture liability from the Balance Sheet Optimization Transaction described in Note 5, remains a structural feature of the income statement in any path.

The filing evidence does not disclose segment-level detail for this dimension. The scenarios rest entirely on the consolidated reported windows rather than any divisional mix. The filing evidence contains no peer or industry comparison. Each scenario must be read against the company's own prior-period windows rather than against a sector benchmark. Investors comparing this profile with other reporters can review Covista Inc. Reports Higher Revenue, Operating Income, Net Income, and Diluted EPS Across the Twelve-Month Period Versus the Prior-Year Comparative, With Each Line Remaining Profitable Year Over Year as a contrasting data point.

The cited evidence does not specify how recurring SG&A recorded under the transition services agreement tied to the P&HS Sale referenced in Note 1, the reimbursable separation costs tied to that same divestiture, or the recurring intangible amortization will evolve, so each scenario treats those as structural items that remain in place until the cited disclosures change.

Risks and what to watch

- The filing under 10-Q for period-ended-2026-06-30 (accession 0001104659-26-093177, CIK 0000075252, ticker ACH) shows a clear split between the headline P&L and the operating-level trends that readers should weigh against the more constructive narrative discussed earlier. - Reported facts: revenue remains positive in dollar terms on both windows. For the three months ended June 30, 2026, revenue of $613,234,000 is lower than the prior-year comparative of $681,917,000.

For the six months ended June 30, 2026, revenue of $1,241,014,000 is lower than the prior-year comparative of $1,355,801,000. Parent net loss narrowed year over year but stayed in loss territory. For the three months ended June 30, 2026, the net loss of -$89,070,000 is smaller than the prior-year net loss of -$869,058,000.

For the six months ended June 30, 2026, the net loss of -$95,537,000 is smaller than the prior-year net loss of -$894,040,000. - Management explanations: the filing continues to present the P&HS business as discontinued operations under Note 1, excluding those results from continuing operations for all periods presented. The cited note Note 2 flags separation costs reimbursed to the Purchaser that flow through exit and realignment charges, net, with corresponding payables sitting in accounts payable and other current liabilities on the condensed consolidated balance sheet.

A transition services agreement is expected to be substantially completed within two years of the P&HS sale, with some services slated to wrap by year-end, while certain TSA activities have already been replaced with internal capabilities and further replacements are planned for the remainder of the year. Fair-value measurement of debt is described using quoted market prices or dealer quotes, or where those are unavailable, on borrowing rates for loans with similar terms, credit ratings, and maturities, with derivative contracts valued via present value of expected future cash flows using observable inputs.

- Analyst inference: revenue compression on both reported windows alongside a still-negative but narrower parent bottom line suggests margin or cost dynamics worth monitoring, even though the top-line decline is the only authorized year-over-year direction on these revenue lines. - Counter-evidence: the cited note Note 2 highlights items that can weigh against the improving loss picture — recurring separation cost reimbursements, ongoing TSA net fees in SG&A, and the continued unwind of transition services. Readers focused solely on the smaller net loss should weigh these carried-forward items, which the cited note frames as ordinary in the context of the P&HS divestiture.

- Unknowns: segment-level detail for revenue and net loss is not disclosed in this filing, and peer or industry context is not provided in the cited evidence. The filing evidence does not attribute revenue or net-loss changes to any single cause. For deeper sensitivity work, the [Covista Inc.

Reports Higher Revenue, Operating Income, Net Income, and Diluted EPS Across the Twelve-Month Period Versus the Prior-Year Comparative, With Each Line Remaining Profitable Year Over Year](/insights/finance/covista-inc-reports-higher-revenue-operating-income-net-income-and-diluted-eps/) piece offers a useful contrast on what a fully profitable peer print looks like across similar windows. - Metrics to watch next period: the trajectory of revenue on both reported windows; whether the parent net loss continues to narrow or stabilizes; the pace of TSA exits and the related SG&A fees; remaining separation cost reimbursements; and any updated fair-value disclosures on debt under Level 1, Level 2, and Level 3.